Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$0.67 +0.4%	$0.66	$0.51 ▼ $1.70	$64.17M	0.29	518,886 shs	196,154 shs
INZY Inozyme Pharma	$4.00	$3.76	$0.72 ▼ $6.24	$258.25M	2.27	950,321 shs	N/A
PRQR ProQR Therapeutics	$2.26 -5.8%	$1.92	$1.07 ▼ $4.62	$252.51M	0.36	662,515 shs	280,471 shs
TRDA Entrada Therapeutics	$6.26 -1.9%	$7.47	$6.23 ▼ $21.79	$242.14M	-0.11	134,454 shs	118,687 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	-1.47%	-5.65%	+1.22%	+9.76%	-59.64%
INZY Inozyme Pharma	0.00%	0.00%	+0.50%	+335.02%	-30.31%
PRQR ProQR Therapeutics	+2.13%	+1.69%	+26.98%	+110.53%	+30.79%
TRDA Entrada Therapeutics	0.00%	-5.62%	-11.51%	-21.53%	-62.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASRT Assertio	2.111 of 5 stars	3.5	0.0	3.0	0.8	1.3
INZY Inozyme Pharma	3.518 of 5 stars	4.2	4.0	2.7	2.5	0.0
PRQR ProQR Therapeutics	2.6141 of 5 stars	3.6	5.0	2.7	0.0	0.0
TRDA Entrada Therapeutics	3.3418 of 5 stars	3.6	1.0	3.0	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASRT Assertio	3.00	Buy	$2.75	308.62% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	193.75% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	253.98% Upside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	310.01% Upside

Current Analyst Ratings Breakdown

Latest ASRT, PRQR, INZY, and TRDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
5/20/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/19/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.50 ➝ $3.50
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/14/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASRT Assertio	$124.96M	0.52	$0.05 per share	13.65	$1.27 per share	0.53
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$0.90 per share	N/A
PRQR ProQR Therapeutics	$20.46M	11.62	N/A	N/A	$0.91 per share	2.48
TRDA Entrada Therapeutics	$210.78M	1.13	$1.56 per share	4.02	$11.46 per share	0.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASRT Assertio	-$21.58M	-$0.32	N/A	22.43	N/A	-25.72%	-24.87%	-10.87%	8/6/2025 (Estimated)
INZY Inozyme Pharma	-$102.02M	-$1.69	N/A	N/A	N/A	N/A	-159.93%	-82.48%	8/5/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.35	N/A	N/A	N/A	-157.04%	-53.49%	-22.07%	8/4/2025 (Estimated)
TRDA Entrada Therapeutics	$65.63M	$0.81	7.73	N/A	N/A	14.39%	5.84%	4.61%	8/12/2025 (Estimated)

Latest ASRT, PRQR, INZY, and TRDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	TRDA Entrada Therapeutics	-$0.86	N/A	N/A	N/A	$8.17 million	N/A
8/6/2025	Q2 2025	ASRT Assertio	-$0.06	N/A	N/A	N/A	$27.86 million	N/A
8/5/2025	Q2 2025	INZY Inozyme Pharma	-$0.36	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/12/2025	Q1 2025	ASRT Assertio	-$0.06	-$0.14	-$0.08	-$0.14	$27.52 million	$26.49 million
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million
5/8/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	-$0.42	+$0.36	-$0.42	$10.98 million	$8.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASRT Assertio	0.36	1.66	1.35
INZY Inozyme Pharma	0.65	2.19	2.19
PRQR ProQR Therapeutics	N/A	4.10	4.10
TRDA Entrada Therapeutics	N/A	21.88	21.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASRT Assertio	48.96%
INZY Inozyme Pharma	88.30%
PRQR ProQR Therapeutics	32.65%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
ASRT Assertio	4.00%
INZY Inozyme Pharma	12.18%
PRQR ProQR Therapeutics	8.40%
TRDA Entrada Therapeutics	8.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASRT Assertio	20	95.78 million	91.95 million	Optionable
INZY Inozyme Pharma	50	64.56 million	56.70 million	Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable
TRDA Entrada Therapeutics	110	37.95 million	34.88 million	Optionable

ASRT, PRQR, INZY, and TRDA Headlines

Recent News About These Companies

5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202k

July 13, 2025 | investing.com

Entrada therapeutics (TRDA) director Parmar sells $202k in stock

July 13, 2025 | investing.com

Ventures V. L.P. 5Am Sells 6,935 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

July 12, 2025 | insidertrades.com

Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 6,935 Shares of Stock

July 11, 2025 | marketbeat.com

Ventures V. L.P. 5Am Sells 20,065 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

July 11, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Sells $202,500.00 in Stock

July 11, 2025 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Shares Down 3.6% - Should You Sell?

July 8, 2025 | marketbeat.com

Entrada Therapeutics (TRDA) 10% owners sell $866k in stock

July 3, 2025 | investing.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 6,422 Shares

July 2, 2025 | insidertrades.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar Sells 75,000 Shares

July 1, 2025 | marketbeat.com

Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 6,422 Shares of Stock

July 1, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 18,578 Shares

July 1, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 19,265 Shares

July 1, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar Sells 25,000 Shares

July 1, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 55,735 Shares

July 1, 2025 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Upgraded to "Hold" at Wall Street Zen

June 27, 2025 | marketbeat.com

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 3, 2025 | globenewswire.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...

May 29, 2025 | morningstar.comM

Entrada Therapeutics to start DMD trial in Q3 2025

May 29, 2025 | investing.com

Entrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025

May 29, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT, PRQR, INZY, and TRDA Company Descriptions

Assertio NASDAQ:ASRT

$0.67 +0.00 (+0.45%)

Closing price 04:00 PM Eastern

Extended Trading

$0.68 +0.00 (+0.59%)

As of 07:49 PM Eastern

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)

As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

ProQR Therapeutics NASDAQ:PRQR

$2.26 -0.14 (-5.83%)

Closing price 04:00 PM Eastern

Extended Trading

$2.26 0.00 (-0.22%)

As of 07:06 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Entrada Therapeutics NASDAQ:TRDA

$6.26 -0.12 (-1.88%)

Closing price 04:00 PM Eastern

Extended Trading

$6.27 +0.01 (+0.16%)

As of 04:04 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time